美国门诊女性滴虫病检测与筛查策略的成本效果分析
该研究构建决策树模型,评估11种基于湿片镜检、快速抗原检测和核酸扩增检测(NAAT)的滴虫病检测/筛查策略,针对2023年美国初级保健机构8000名15-59岁女性。对有症状女性,湿片镜检加做NAAT具有成本效果(ICER:83,097美元/QALY),而快速抗原检测加做NAAT不具有成本效果;对无症状女性,NAAT筛查不具有成本效果(403,541美元/QALY)。
要点
- 有症状女性湿片镜检加做NAAT在10万美元/QALY阈值下具有成本效果。
- 有症状女性快速抗原检测加做NAAT不具有成本效果。
- 无症状女性NAAT筛查不具有成本效果。
核心结论
- 对有症状女性,在现行检测中加做NAAT可改善健康结局但增加成本;在10万美元/QALY支付意愿阈值下,湿片镜检加做NAAT具有成本效果,而快速抗原检测加做NAAT不具有成本效果。
- 对无症状女性,普遍NAAT筛查不具有成本效果,提示更广泛的筛查策略可能需要更高的支付意愿阈值才具有经济合理性。
研究设计与样本
- 决策树模型,评估11种检测/筛查策略(湿片镜检、快速抗原检测和NAAT的组合),针对2023年美国初级保健诊所8000名15-59岁女性的假设队列,估算终生健康风险、社会经济负担和QALY损失。
主要发现
- 对有症状女性,湿片镜检加做NAAT额外获得0.3 QALYs,增量成本24,785美元(ICER:83,097美元/QALY)。
- 对有症状女性,快速抗原检测加做NAAT额外获得0.1 QALYs,增量成本35,628美元(ICER:324,617美元/QALY)。
- 对无症状女性,NAAT筛查成本为403,541美元/QALY。
关键数值与推荐
- 支付意愿阈值为10万美元/QALY。
- 有症状女性湿片镜检加做NAAT的ICER为83,097美元/QALY,具有成本效果。
- 有症状女性快速抗原检测加做NAAT的ICER为324,617美元/QALY,不具有成本效果。
- 无症状女性NAAT筛查的成本为403,541美元/QALY,不具有成本效果。
临床怎么用
- 对有症状女性,可考虑在湿片镜检基础上加做NAAT以改善健康结局,该策略在10万美元/QALY阈值下具有成本效果。
- 对有症状女性,不建议在快速抗原检测基础上加做NAAT,因其不具有成本效果。
- 对无症状女性,不建议进行普遍NAAT筛查,因其不具有成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: T. vaginalis, the most common non-viral sexually transmitted infection among women, is associated with multiple adverse health outcomes. Screening asymptomatic women is not recommended except among HIV-infected women. We aimed to evaluate the cost-effectiveness of T. vaginalis testing and screening strategies among asymptomatic and symptomatic women, respectively, in U.S. primary care settings. METHODS: We developed a decision tree model to evaluate 11 testing/screening strategies (using combinations of wet mount microscopy, rapid antigen testing, and T. vaginalis nucleic acid amplification testing [NAAT]) for a hypothetical cohort of 8,000 women aged 15-59 years presenting to U.S. primary care clinics in 2023. We estimated the risk, societal economic burden, and quality-adjusted life year (QALY) losses for trichomonas sequelae-preterm birth, low birthweight, premature rupture of membranes, HIV infection, and cervical cancer-over the cohort's lifetime. RESULTS: Adding T. vaginalis NAAT to wet mount for symptomatic women provided 0.3 additional QALYs at an incremental cost of $24,785 (ICER: $83,097/QALY). Adding NAAT to rapid antigen testing for symptomatic women yielded 0.1 additional QALYs at an incremental cost of $35,628 (ICER: $324,617/QALY). Screening asymptomatic women with NAAT cost $403,541/QALY. CONCLUSIONS: Incorporating NAAT into current testing practices for symptomatic women improved health outcomes but increased costs. At a willingness-to-pay threshold of $100,000/QALY, adding NAAT to wet mount for symptomatic women was cost-effective whereas adding NAAT to rapid antigen testing was not. Universal NAAT screening among asymptomatic women was also not cost-effective, suggesting that broader screening strategies may require substantially higher willingness-to-pay thresholds to be economically justified.
引用
- Rong R, Stoecker C, Kissinger PJ, et al. Cost-Effectiveness of Testing and Screening Strategies for Trichomoniasis among Asymptomatic and Symptomatic Women in U.S. Outpatient Clinical Settings. Clin Infect Dis. 2026. PMID: 42570009. doi:10.1093/cid/ciag465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。